Morgan Stanley
CAMP icon

Morgan Stanley’s CAMP4 Therapeutics CAMP Stock Holding History

Morgan Stanley’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.9K Sell
9,505
-409
-4% -$1.94K ﹤0.01% 6484
2025
Q4 		$60.8K Buy
9,914
+9,911
+330,367% +$42.2K ﹤0.01% 6374
2025
Q3 		$9 Sell
3
-1,684
-100% -$3.12K ﹤0.01% 8103
2025
Q2 		$2.45K Sell
1,687
-7,285
-81% -$14.5K ﹤0.01% 7182
2025
Q1 		$35.9K Sell
8,972
-5,289
-37% -$25.6K ﹤0.01% 6378
2024
Q4 		$74.4K Buy
+14,261
New +$117K ﹤0.01% 6161

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley's CAMP Position: Q1 2026 in Review

Morgan Stanley reduced its CAMP4 Therapeutics (CAMP) stake by 4.1% in Q1 2026, selling an estimated $1.94K and leaving 9,505 shares worth $41.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6484.

Morgan Stanley first reported a position in CAMP in Q4 2024 and has held it in 6 quarters since. The position peaked at $74.4K in Q4 2024. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Morgan Stanley held 9,505 shares of CAMP4 Therapeutics worth $41.9K as of Q1 2026.
  • Morgan Stanley sold 409 CAMP4 Therapeutics shares in Q1 2026, an estimated $1.94K.
  • CAMP4 Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6484 holding.
  • Morgan Stanley first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Morgan Stanley's CAMP4 Therapeutics position peaked at $74.4K in Q4 2024.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.